United Therapeutics (UTHR) Receives CRL from FDA for Oral Treprostinil
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
JPMorgan Downgrades United Therapeutics Corp. (UTHR) to Underweight
October 24, 2012 6:49 AM EDTJPMorgan downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Underweight with a price target of $40.00 (from $50.00) following CRL from FDA for Oral Treprostinil.
For an analyst ratings summary and ratings history on United Therapeutics Corp.... More
BMO Capital Downgrades United Therapeutics Corp. (UTHR) to Market Perform
October 24, 2012 6:48 AM EDTBMO Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Outperform to Market Perform following CRL from FDA for Oral Treprostinil
For an analyst ratings summary and ratings history on United Therapeutics Corp. click... More
